GTC Raises $10M from LFB Biotech

Xconomy Boston — 

Framingham, MA-based GTC Biotherapeutics (NASDAQ:GTCB) said it has raised $10 million through the sale of its shares to French biotech drug maker LFB Biotechnologies, a major shareholder in GTC. GTC chief executive Christian Béchon also revealed in a statement that the company planned to reduce expenses by $5 million to $6 million in 2010, focusing resources on its recombinant human antithrombin (ATryn) and Factor VIIa products. This morning a company spokesman declined to provide details on the actions GTC plans to take to reduce its expenses.